This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bernard, S. A. Articles by Bruera, E. Search for Related Content PubMed PubMed Citation Articles by Bernard, S. A. Articles by Bruera, E.

Drug Interactions in Palliative Care

From the Division of Hematology/Medical OncologyUniversity of North Carolina, Chapel Hill, NC, and Department of Symptom Control and Palliative Care, University of Texas, M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Eduardo Bruera, MD, Department of Symptom Control and Palliative Care, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Room P12.2911, Houston, TX 77030; email ebruera{at}notes.mdacc.tmc.edu

PURPOSE: This review of drug interactions in palliative care examines the relevant literature in this area and summarizes the information on interactions of drugs, nutrients, and natural products that are used in the palliative care setting. Particular emphasis is placed on describing the newer information on the cytochrome P450 (CYP) system and the interactions of opioids, antidepressants, and the antitussive, dextromethorphan.

METHODS: We performed a search of the MEDLINE database of the time period from 1966 until April 1998, using medical subject headings such as the names of selective serotonin reuptake inhibitors and other relevant medications in palliative care. Literature reviewed included both human and animal articles as well as non-English literature. Bibliographies of these articles and the personal libraries of several palliative care specialists were reviewed. Software developed by The Medical Letter—The Drug Interaction Program was also used.

RESULTS: Drug interactions can be categorized in several ways. Drug-drug interactions are the most well known and can be kinetic, dynamic, or pharmaceutical. Pharmacokinetic interactions can involve CYP 2D6, which acts on drugs such as codeine and is responsible for its conversion to morphine. Poor metabolizers, either genotypic or due to phenocopying, are at risk for undertreatment if not recognized. Pharmacodynamic interactions with dextromethorphan may produce serotonin syndrome.

CONCLUSION: Drug interactions are important in palliative care as in other aspects of medicine. These interactions are similar to those seen in other areas of medical care but have significant consequences in pain management. Failure to recognize these interactions can lead to either overdosing or undertreatment.

This article has been cited by other articles:

				F Skorpen, E. Laugsand, P Klepstad, and S Kaasa Variable response to opioid treatment: any genetic predictors within sight? Palliative Medicine, June 1, 2008; 22(4): 310 - 327. [Abstract] [PDF]

				S. P. Lee, K. T. Bain, and V. Maio Appropriate Discontinuation of Medications at the End of Life: A Need to Establish Consensus Criteria American Journal of Medical Quality, December 1, 2007; 22(6): 393 - 394. [PDF]

				G. J. Wood, J. W. Shega, B. Lynch, and J. H. Von Roenn Management of Intractable Nausea and Vomiting in Patients at the End of Life: "I Was Feeling Nauseous All of the Time . . . Nothing Was Working" JAMA, September 12, 2007; 298(10): 1196 - 1207. [Abstract] [Full Text] [PDF]

				F. G. A. Jansman, A. J. A. Jansen, J. L. L. Coenen, J. C. de Graaf, W. M. Smit, D. T. Sleijfer, and J. R. B. Brouwers Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer Am. J. Health Syst. Pharm., September 1, 2005; 62(17): 1788 - 1793. [Full Text] [PDF]

				T. Akechi, T. Okuyama, Y. Sugawara, T. Nakano, Y. Shima, and Y. Uchitomi Major Depression, Adjustment Disorders, and Post-Traumatic Stress Disorder in Terminally Ill Cancer Patients: Associated and Predictive Factors J. Clin. Oncol., May 15, 2004; 22(10): 1957 - 1965. [Abstract] [Full Text] [PDF]

				A. J Coop Comment: electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists Ann. Pharmacother., December 1, 2003; 37(12): 1918 - 1918. [Full Text] [PDF]

				V. L. Ghafoor Treatment of Chronic Pain Journal of Pharmacy Practice, August 1, 2003; 16(4): 249 - 260. [Abstract] [PDF]

				N. Cherny, C. Ripamonti, J. Pereira, C. Davis, M. Fallon, H. McQuay, S. Mercadante, G. Pasternak, and V. Ventafridda Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report J. Clin. Oncol., May 1, 2001; 19(9): 2542 - 2554. [Abstract] [Full Text] [PDF]

				C. Mazzocato, C. Sweeney, and E. Bruera Clinical research in palliative care: Patient populations, symptoms, interventions and endpoints Palliative Medicine, March 1, 2001; 15(2): 163 - 168. [PDF]